TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:50
BIODESIX INC ( BDSX ) https://www.biodesix.com
1.46USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-23.16%
BDSX
SPY
32.66%
-64.82%
BDSX
SPY
108.59%
BDSX
0.00%
SPY
302.52%
BDSX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
229.68
234.39
0.14
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.24
3.50
8.25
-28.21
0.00
-7.39
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-47.33
100.00
-45.91
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-61.32
-53.69
0.00
Other Earnings and Cash Flow Stats:
BIODESIX INC ( BDSX ) Net Income TTM ($MM) is -43.82
BIODESIX INC ( BDSX ) Operating Income TTM ($MM) is -34.70
BIODESIX INC ( BDSX ) Owners' Earnings Annual ($MM) is -37.71
BIODESIX INC ( BDSX ) Current Price to Owners' Earnings ratio is -4.01
BIODESIX INC ( BDSX ) EBITDA TTM ($MM) is -29.65
BIODESIX INC ( BDSX ) EBITDA Margin is -45.91%
Capital Allocation:
BIODESIX INC ( BDSX ) has paid 0.00 dividends per share and bought back -66.587 million shares in the past 12 months
BIODESIX INC ( BDSX ) has reduced its debt by 15.75 million USD in the last 12 months
Capital Structure:
BIODESIX INC ( BDSX ) Interest-bearing Debt ($MM) as of last quarter is 36
BIODESIX INC ( BDSX ) Annual Working Capital Investments ($MM) are -4
BIODESIX INC ( BDSX ) Book Value ($MM) as of last quarter is 27
BIODESIX INC ( BDSX ) Debt/Capital as of last quarter is 129%
Other Balance Sheet Stats:
BIODESIX INC ( BDSX ) has 31 million in cash on hand as of last quarter
BIODESIX INC ( BDSX ) has 12 million of liabilities due within 12 months, and long term debt 35 as of last quarter
BIODESIX INC ( BDSX ) has 146 common shares outstanding as of last quarter
BIODESIX INC ( BDSX ) has 0 million USD of preferred stock value
Academic Scores:
BIODESIX INC ( BDSX ) Altman Z-Score is -4.49 as of last quarter
BIODESIX INC ( BDSX ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
BIODESIX INC ( BDSX ) largest shareholder is owning shares at 0.00 ($MM) value
SCHULER JACK W(an insider) Bought 100000 shares of BIODESIX INC ( BDSX ) for the amount of $122840.00 on 2024-11-21
47.20% of BIODESIX INC ( BDSX ) is held by insiders, and 34.86% is held by institutions
BIODESIX INC ( BDSX ) went public on 2020-10-28
Other BIODESIX INC ( BDSX ) financial metrics:
FCF:-61.34
Unlevered Free Cash Flow:-66.21
EPS:-0.28
Operating Margin:-47.33
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-147.30
Beta:0.00
Buffet's Owners Earnings:-37.71
Price to Owner's Earnings:-4.01
About BIODESIX INC ( BDSX ) :
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.